Marksans Pharma jumps on getting USFDA`s final approval for Guaifenesin Extended-Release Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Marksans Pharma is currently trading at Rs. 112.75, up by 3.05 points or 2.78% from its previous closing of Rs. 109.70 on the BSE.
The scrip opened at Rs. 110.00 and has touched a high and low of Rs. 114.75 and Rs. 110.00 respectively. So far 308136 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 122.50 on 10-Aug-2023 and a 52 week low of Rs. 45.65 on 11-Oct-2022.
Last one week high and low of the scrip stood at Rs. 116.70 and Rs. 108.80 respectively. The current market cap of the company is Rs. 5098.09 crore.
The promoters holding in the company stood at 43.85%, while Institutions and Non-Institutions held 18.56% and 37.59% respectively.
Marksans Pharma has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg (OTC)
The Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg (OTC) are bioequivalent to the reference listed drug (RLD), Mucinex Extended-Release Tablets, 600 mg and 1200 mg, of RB Health (US) LLC. Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive. The company expects to launch the product immediately.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
